Literature DB >> 26201526

Circulating endotoxin and interleukin-6 levels are associated with Doppler-evaluated pulmonary vascular resistance in cirrhotic patients.

Georgios N Kalambokis1, Athanasia Mouzaki2, Maria Rodi2, Konstantinos Pappas3, Panagiotis Korantzopoulos3, Epameinondas V Tsianos4.   

Abstract

PURPOSE: Endotoxin and interleukin-6 levels (IL-6) have been involved in the development of pulmonary hypertension (PH) in non-cirrhotic experimental models and subjects. High circulating levels of both substances have been detected in cirrhosis. The association between circulating endotoxin and IL-6 levels and echocardiographically evaluated pulmonary vascular resistance (PVR) in cirrhotic patients are investigated.
METHODS: Thirty-seven cirrhotic patients were studied: 25 with PVR <120 dynes s cm(-5) (group 1) and 12 with PVR >120 dynes s cm(-5) (group 2). Plasma endotoxin and serum IL-6 levels were measured. The PVR and cardiac output (CO) by Doppler ultrasound, mean arterial pressure (MAP), and systemic vascular resistance (SVR) as the ratio MAP/CO were evaluated.
RESULTS: Child-Pugh scores, MAP, CO, and SVR were similar in both groups. Endotoxin levels were correlated significantly with IL-6 levels (r = 0.342; P = 0.03). Endotoxin and IL-6 levels were significantly higher in group 2 compared to group 1 (2.26 [0.39-8.4] vs. 0.85 [0.37-7.6] EU/mL; P = 0.04 and 37.4 [7.85-106.5] vs. 8.36 [3.15-53.7] pg/mL; P < 0.001, respectively). The PVR was correlated significantly with endotoxin levels in group 2 (r = 0.587; P = 0.04) and with IL-6 levels in group 1 (r = 0.529; P = 0.01) and group 2 (r = 0.760; P = 0.004), respectively.
CONCLUSIONS: Our results suggest that endotoxin and IL-6 may contribute to cirrhosis-associated PH. In this regard, modulation of these substances could improve pulmonary pressures in cirrhotic patients.

Entities:  

Keywords:  Cirrhosis; Endotoxin; Interleukin-6; Pulmonary hypertension

Year:  2012        PMID: 26201526     DOI: 10.1007/s12072-011-9337-0

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  43 in total

1.  New approach to an ovine model of hypodynamic endotoxaemia.

Authors:  M Westphal; F Daudel; H G Bone; H Van Aken; J Sander; H Stubbe; M Booke
Journal:  Eur J Anaesthesiol       Date:  2004-08       Impact factor: 4.330

2.  Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide.

Authors:  C J Chu; F Y Lee; S S Wang; R H Lu; Y T Tsai; H C Lin; M C Hou; C C Chan; S D Lee
Journal:  Clin Sci (Lond)       Date:  1997-09       Impact factor: 6.124

3.  Accurate noninvasive estimation of pulmonary vascular resistance by Doppler echocardiography in patients with chronic failure heart failure.

Authors:  F Scapellato; P L Temporelli; E Eleuteri; U Corrà; A Imparato; P Giannuzzi
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

Review 4.  Evolving dilemmas and management of portopulmonary hypertension.

Authors:  Michael J Krowka
Journal:  Semin Liver Dis       Date:  2006-08       Impact factor: 6.115

Review 5.  Portopulmonary hypertension.

Authors:  Jason M Golbin; Michael J Krowka
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

6.  Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis.

Authors:  J Devière; J Content; C Denys; P Vandenbussche; L Schandene; J Wybran; E Dupont
Journal:  Hepatology       Date:  1990-04       Impact factor: 17.425

7.  Vascular endothelial cells synthesize nitric oxide from L-arginine.

Authors:  R M Palmer; D S Ashton; S Moncada
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

8.  Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension.

Authors:  N Selimovic; C-H Bergh; B Andersson; E Sakiniene; H Carlsten; B Rundqvist
Journal:  Eur Respir J       Date:  2009-03-26       Impact factor: 16.671

9.  Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis.

Authors:  C Müller; C C Zielinski
Journal:  J Hepatol       Date:  1992-07       Impact factor: 25.083

10.  Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation.

Authors:  F Y Lee; R H Lu; Y T Tsai; H C Lin; M C Hou; C P Li; T M Liao; L F Lin; S S Wang; S D Lee
Journal:  Scand J Gastroenterol       Date:  1996-05       Impact factor: 2.423

View more
  2 in total

Review 1.  Endotoxins and Non-Alcoholic Fatty Liver Disease.

Authors:  Takaomi Kessoku; Takashi Kobayashi; Kento Imajo; Kosuke Tanaka; Atsushi Yamamoto; Kota Takahashi; Yuki Kasai; Anna Ozaki; Michihiro Iwaki; Asako Nogami; Yasushi Honda; Yuji Ogawa; Shingo Kato; Takuma Higurashi; Kunihiro Hosono; Masato Yoneda; Takayuki Okamoto; Haruki Usuda; Koichiro Wada; Noritoshi Kobayashi; Satoru Saito; Atsushi Nakajima
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-29       Impact factor: 5.555

2.  Portopulmonary hypertension in cirrhotic patients: Prevalence, clinical features and risk factors.

Authors:  Hui-Song Chen; Su-Rong Xing; Wei-Guo Xu; Fan Yang; Xiao-Long Qi; LE-Min Wang; Chang-Qing Yang
Journal:  Exp Ther Med       Date:  2013-01-22       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.